Selective anticancer agents suppress aging in  Drosophila

Anton Danilov; Mikhail Shaposhnikov; Ekaterina Plyusnina; Valeria Kogan; Peter Fedichev; Alexey Moskalev

doi:10.18632/oncotarget.1272

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Selective anticancer agents suppress aging in Drosophila

Anton Danilov, Mikhail Shaposhnikov, Ekaterina Plyusnina, Valeria Kogan, Peter Fedichev and Alexey Moskalev _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2013; 4:1507-1526. https://doi.org/10.18632/oncotarget.1272

Metrics: PDF 2399 views | HTML 6237 views | ?

Abstract

Anton Danilov1, Mikhail Shaposhnikov1,2, Ekaterina Plyusnina1,2, Valeria Kogan3,4, Peter Fedichev3,4 and Alexey Moskalev1,2,3

1 Institute of Biology, Komi Science Center, Russian Academy of Sciences, Syktyvkar, 167982, Russia

2 Syktyvkar State University, Syktyvkar, 167001, Russia

3 Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, 141700, Russia

4 Quantum Pharmaceuticals, Ul. Kosmonavta Volkova 6A-1205, Moscow, 125171, Russia

Correspondence:

Alexey Moskalev, email:

Keywords: longevity, quality of life, aging-suppressive substances, anticancer agents, PI3K, TOR, iNOS, NF-κB, Drosophila melanogaster

Received: August 10, 2013 Accepted: September 6, 2013 Published: September 7, 2013

Abstract

Mutations of the PI3K, TOR, iNOS, and NF-κB genes increase lifespan of model organisms and reduce the risk of some aging-associated diseases. We studied the effects of inhibitors of PI3K (wortmannin), TOR (rapamycin), iNOS (1400W), NF-κB (pyrrolidin dithiocarbamate and QNZ), and the combined effects of inhibitors: PI3K (wortmannin) and TOR (rapamycin), NF-κB (pyrrolidin dithiocarbamates) and PI3K (wortmannin), NF-κB (pyrrolidine dithiocarbamates) and TOR (rapamycin) on Drosophila melanogaster lifespan and quality of life (locomotor activity and fertility). Our data demonstrate that pharmacological inhibition of PI3K, TOR, NF-κB, and iNOS increases lifespan of Drosophila without decreasing quality of life. The greatest lifespan expanding effect was achieved by a combination of rapamycin (5 μM) and wortmannin (5 μM) (by 23.4%). The bioinformatic analysis (KEGG, REACTOME.PATH, DOLite, and GO.BP) showed the greatest aging-suppressor activity of rapamycin, consistent with experimental data.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1272

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Selective anticancer agents suppress aging in Drosophila

Abstract